Canakinumab in pediatric rheumatic diseases

Rilonacept for Colchicine-Resistant or -Intolerant Familial Mediterranean Fever

(2013) Philip J. Hashkes et al.   ANNALS OF INTERNAL MEDICINE

The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis

(2012) Dirk Holzinger et al.   ANNALS OF THE RHEUMATIC DISEASES

An International registry on Autoinflammatory diseases: the Eurofever experience

(2012) Natasa Toplak et al.   ANNALS OF THE RHEUMATIC DISEASES

Rates of malignancy associated with juvenile idiopathic arthritis and its treatment

(2012) Timothy Beukelman et al.   ARTHRITIS AND RHEUMATISM

Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis

(2012) Nicolino Ruperto et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis

(2012) Fabrizio De Benedetti et al.   NEW ENGLAND JOURNAL OF MEDICINE

Algorithm development for corticosteroid management in systemic juvenile idiopathic arthritis trial using consensus methodology

(2012) Norman T Ilowite et al.   Pediatric Rheumatology

Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: Results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study

(2012) H. Ralph Schumacher et al.   ARTHRITIS CARE & RESEARCH

Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes

(2011) J. B. Kuemmerle-Deschner et al.   ANNALS OF THE RHEUMATIC DISEASES

A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features

(2011) Nicolino Ruperto et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1β antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a phase III study

(2011) N Ruperto et al.   Pediatric Rheumatology

2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features

(2011) Timothy Beukelman et al.   ARTHRITIS CARE & RESEARCH

Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study

(2011) Isabelle Koné-Paut et al.   ARTHRITIS RESEARCH & THERAPY

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

(2010) P. Quartier et al.   ANNALS OF THE RHEUMATIC DISEASES

Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: Report of forty-six patients from an international multicenter series

(2010) Peter A. Nigrovic et al.   ARTHRITIS AND RHEUMATISM

The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis

(2010) Joost Frans Swart et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Unknown

(2010) Gianfranco Ferraccioli et al.   MOLECULAR MEDICINE

Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis

(2009) E. H. Giannini et al.   ARTHRITIS AND RHEUMATISM

Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis

(2009) Michael G. Barnes et al.   ARTHRITIS AND RHEUMATISM

The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1β form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis

(2009) Michael Frosch et al.   ARTHRITIS AND RHEUMATISM

Identification of a novel susceptibility locus for juvenile idiopathic arthritis by genome-wide association analysis

(2009) Anne Hinks et al.   ARTHRITIS AND RHEUMATISM

Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome

(2009) Bénédicte Neven et al.   ARTHRITIS AND RHEUMATISM

In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes

(2009) Helen J. Lachmann et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome

(2009) Helen J. Lachmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

The pattern of response to anti–interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis

(2008) Marco Gattorno et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebo-controlled studies

(2008) Hal M. Hoffman et al.   ARTHRITIS AND RHEUMATISM

Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study

(2008) Norman Ilowite et al.   CLINICAL RHEUMATOLOGY